Table 1.
Association of MYBL2 expression levels with clinicopathologic characteristics in EC.
| Factors | MYBL2 protein expression | p | |||
|---|---|---|---|---|---|
| Low (n=68) | High (n=72) | ||||
| Count | % | Count | % | ||
| Age (years) | |||||
| >60 | 17 | 12.10 | 18 | 12.90 | 1 |
| ≤60 | 51 | 36.40 | 54 | 38.60 | |
| Menopause status* | |||||
| Peri/Pre | 5 | 3.60 | 6 | 4.30 | 0.829 |
| Fost | 63 | 45.00 | 66 | 47.10 | |
| Histological type | |||||
| Type I | 46 | 32.90 | 26 | 25.70 | 0.034 |
| Type II | 22 | 15.70 | 36 | 25.70 | |
| Clinical stage | |||||
| Type I | 42 | 30.00 | 38 | 27.10 | 0.283 |
| Type II-IV | 26 | 18.60 | 34 | 24.30 | |
| Histologic Grade | |||||
| G1-G2 | 23 | 16.40 | 5 | 3.60 | <0.001 |
| G3-G4 | 45 | 32.10 | 67 | 47.90 | |
*Peri, 6-12 months since last menstrual period (LMP); Pre,<6 months since LMP and no prior bilateral ovariectomy and not on estrogen replacement; Post, prior bilateral ovariectomy or >12 months since LMP with no prior hysterectomy.